Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Interferon Alpha-2: Pre-Clinical and Clinical Evaluation by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781461325796
Publisher: Springer US Publication: December 6, 2012
Imprint: Springer Language: English
Author:
ISBN: 9781461325796
Publisher: Springer US
Publication: December 6, 2012
Imprint: Springer
Language: English

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

More books from Springer US

Cover of the book Design Review by
Cover of the book Physiologic and Chemical Basis for Metal Toxicity by
Cover of the book Mechanics and Energetics of the Myocardium by
Cover of the book Blood Cell Biochemistry by
Cover of the book Superconducting Electron-Optic Devices by
Cover of the book Social Justice in Human Relations Volume 2 by
Cover of the book Hardware/Software Co-Design and Co-Verification by
Cover of the book Time Pressure and Stress in Human Judgment and Decision Making by
Cover of the book Heme Oxygenase in Biology and Medicine by
Cover of the book The Neurochemical Basis of Autism by
Cover of the book Fluid Effects in Polymers and Polymeric Composites by
Cover of the book Integrated Cost and Schedule Control for Construction Projects by
Cover of the book Power-Aware Testing and Test Strategies for Low Power Devices by
Cover of the book Metabolic Effects of Gonadal Hormones and Contraceptive Steroids by
Cover of the book Opioid Dependence by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy